Close

Merck's (MRK) KEYTRUDA (pembrolizumab) Demonstrates Improved OS at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial

May 31, 2019 6:48 AM EDT Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the final analysis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login